Related Experiment Video
Updated: Oct 9, 2025
09:44
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
3.1K
THE EFFECT OF MYOINOSITOL AND METFORMIN ON CARDIOVASCULAR RISK FACTORS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A
V Soldat-Stankovic1, S Popovic Pejicic1, S Stankovic2
1University Clinical Centre of the Republic of Srpska - Internal medicine, Bosnia and Herzegovina.
Acta Endocrinologica (Bucharest, Romania : 2005)
|December 20, 2021
Summary
Myoinositol (MI) improved diastolic blood pressure and total cholesterol in women with polycystic ovary syndrome (PCOS), while metformin (MET) reduced hyperandrogenism markers. Both treatments impacted body mass index and waist circumference.
Area of Science:
- Endocrinology
- Metabolic Syndrome
- Cardiovascular Health
Background:
- Polycystic ovary syndrome (PCOS) is associated with increased cardiovascular risk in women.
- Insulin sensitizing agents are explored for their potential to mitigate these risks.
Purpose of the Study:
- To compare the effects of myoinositol (MI) and metformin (MET) on cardiovascular risk biomarkers in women with PCOS.
- To assess the impact of these agents on blood pressure, lipid profile, and hs-CRP in relation to body mass index (BMI).
Main Methods:
- An open-label, parallel randomized study involving 66 women with PCOS (normal-weight and overweight/obese).
- Participants received either MI (4 g/day) or MET (1500 mg/day) for 6 months.
- Key biomarkers including blood pressure, lipid profile, hs-CRP, BMI, and hormonal levels were measured pre- and post-treatment.
Main Results:
- MI significantly reduced diastolic blood pressure (DBP) and total cholesterol (TC), and also decreased BMI and waist circumference (WC).
- MET significantly decreased BMI, WC, Ferriman Gallwey score, testosterone, and free androgen index (FAI).
- MI showed a significant increase in hs-CRP, while no significant differences were observed between groups for HDL-cholesterol, LDL-cholesterol, ox-LDL, and triglycerides.
Conclusions:
- Myoinositol (MI) demonstrates an advantage in reducing diastolic blood pressure and total cholesterol, suggesting favorable metabolic and cardiovascular outcomes for women with PCOS.
- Metformin (MET) is more effective in decreasing hyperandrogenism indices.
- Both agents show positive effects on body composition metrics like BMI and waist circumference.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
336
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
336
02:07Oogenesis
65.5K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
65.5K